Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation

by Farinaz Keshavarzi, Tony Fox, Eromona Whiskey, David Taylor
Published 2020-01-01

Management of clozapine treatment during the COVID-19 pandemic

by Siobhan Gee, Fiona Gaughran, James MacCabe, Sukhi Shergill, Eromona Whiskey, David Taylor
Published 2020-05-01

Resolution without discontinuation: heart failure during clozapine treatment

by Eromona Whiskey, Shirley Yuen, Emma Khosla, Susan Piper, David O’Flynn, David Taylor
Published 2020-06-01

Possible pharmacogenetic factors in clozapine treatment failure: a case report

by Eromona Whiskey, Graziella Romano, Matilda Elliott, Malcolm Campbell, Cholan Anandarajah, David Taylor, Koravangattu Valsraj
Published 2021-07-01

Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report

by Victoria Rodriguez, Kieran Hanley, Ana Julia Arias, Diego Quattrone, Joseph Kuforiji, Eromona Whiskey, Sukhi S. Shergill
Published 2020-05-01

Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled...

by Fiona Gaughran, Dominic Stringer, Michael Berk, Shubulade Smith, David Taylor, Eromona Whiskey, Sabine Landau, Robin Murray, Philip McGuire, Poonam Gardner-Sood, Gabriella Wojewodka, Simone Ciufolini, Harriet Jordan, Jessie Clarke, Lauren Allen, Amir Krivoy, Brendon Stubbs, Philippa Lowe, Maurice Arbuthnott, Shanaya Rathod, Andrew Boardman, Mudasir Firdosi, John J. McGrath
Published 2020-01-01